StockData
Zoetis Inc. logo

Zoetis Inc. (ZTS) KPIs and segments

ZTSNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 17/3046% below fair value
$85.57+2.09 (+2.50%)

Close on Nov 18, 2026Market cap $35.36BP/E 14.1Yield 2.37%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Zoetis · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026; effective FY2026, international subsidiaries aligned from a November 30 fiscal year-end to December 31)

Nhìn nhanh KPI của Zoetis: 42 chỉ số vận hành, trong đó có Total Consolidated Revenue, U.S. Operating Segment Revenue và International Operating Segment Revenue, lấy từ 164 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
U.S.($M)2
1,2661,0901,2361,3221,3561,1831,2571,3461,3081,1631,211
Companion animal($M)
1,0448651,0021,0691,1769731,0081,0681,080898941
Livestock($M)
222225234253180210249278228265270
International($M)2
1,1731,1491,1211,0551,0859851,0391,0211,0351,007982
Companion animal($M)
664654599583614568562541569552507
Livestock($M)
509495522472471417477480466455475
Companion animal($M)
1,7081,5191,6011,6521,7901,5411,5701,6091,6491,4501,448
Dogs and Cats($M)
1,6341,4431,5861,7191,4771,5511,5811,384
Livestock($M)
731720756725651627726758694720745
Parasiticides($M)
698586542564660572519530600504482
Vaccines($M)
521519512496510439462468445452463
Dermatology($M)
398349429472473379421453418363379
Cattle($M)
390392415399323341399391350391401
Anti-infectives($M)
244241284284222238281274264281261
Pain and sedation($M)
217203209204223207217219221194194
Other pharmaceutical($M)
168158188178175158180169153156164
Animal health diagnostics($M)
1231171111101101041001011038292
Swine($M)
117123125111118105128131130127139
Poultry($M)
115118117106104106117139132139127
Fish($M)
8366817881556570624562
Horses($M)
74766,0806671645,8015868665,094
Other non-pharmaceutical($M)
7066706468716562656161
Contract manufacturing & human health($M)
29233023333021211820
Sheep and other($M)
2621183125201727201816
Medicated feed additives($M)
125555191747797
United States($M)
1,2661,0901,2361,3221,3561,1831,2571,3461,3081,1631,211
Other emerging markets($M)
269291212228223238195220222228179
Other developed markets($M)
187169182164175133151148138127138
Brazil($M)
10390112100938111310199101117
Australia($M)
9489848783798083837375
Canada($M)
7273807071707566756172
United Kingdom($M)
7278898281748480737768
Germany($M)
6959656257555957585154
China($M)
6263504567556561687665
Mexico($M)
4748444139354039464443
Spain($M)
4340373840293035333228
Japan($M)
4135393443323833393738
France($M)
4037524042394536344140
Italy($M)
4039353537303431362834
Chile($M)
3438402934353031313131
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
U.S.($M)
1,0528961,0231,1001,1489841,0281,0881,076946956
International($M)
833815756724764690703700693694660
U.S.($M)
837697830899930779819889872756766
International($M)
661639574556592527523542518535494
Other business activities($M)
-141-159-140-134-133-151-137-142-132-142
Total Consolidated Revenue ($M)($M)8
2,3912,4682,2622,3872,4002,4602,2202,3172,3882,3612,1902,213
Total Product & Service Revenue (Reportable Segments: U.S. + International) ($M)($M)
2,3622,4392,2392,3572,3962,4412,1682,2962,3672,3432,1702,193
Contract Manufacturing & Human Health Revenue ($M)($M)5
292923302334292121182020
Contract Manufacturing & Human Health Revenue — Reported growth YoY (%)(%)
12.0%-12.0%-23.0%43.0%10.0%89.0%45.0%5.0%0.0%-10.0%18.0%-26.0%
Contract Manufacturing & Human Health Revenue — Foreign exchange impact YoY (%)(%)
-3.0%1.0%1.0%6.0%0.0%-2.0%-6.0%0.0%-2.0%-1.0%2.0%1.0%
Contract Manufacturing & Human Health Revenue — Operational (constant-currency) growth YoY (%)(%)
15.0%-13.0%-24.0%37.0%10.0%91.0%51.0%5.0%2.0%-9.0%16.0%-27.0%
Contract Manufacturing & Human Health Revenue — Divestitures impact YoY (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Contract Manufacturing & Human Health Revenue — Organic operational growth YoY (%)(%)
15.0%-13.0%-24.0%37.0%10.0%91.0%51.0%5.0%2.0%-9.0%16.0%-27.0%
MD&A Operational Revenue Change YoY ($M)($M)6
-44-41-12206216103297243239
MD&A Reported Revenue Change YoY ($M)($M)
-31-66414112930237181190
MD&A Foreign Exchange Impact on Revenue YoY ($M)($M)
133576
MD&A Revenue Driver — Volume from Key Franchises Contribution (%)(%)
-1.0%-3.0%-3.0%4.0%2.0%2.0%3.0%
MD&A Revenue Driver — Volume from Other In-Line Products Contribution (%)(%)
1.0%2.0%1.0%1.0%3.0%-2.0%-2.0%
MD&A Revenue Driver — MFA Divestiture Volume Impact (%)(%)
-1.0%-1.0%-1.0%-4.0%
MD&A Revenue Driver — Volume from New Products [legacy through FY24] (%)(%)
3.0%3.0%4.0%
Total Consolidated Revenue — Reported growth YoY (%)(%)
-1.0%0.0%3.0%3.0%1.0%4.0%1.0%5.0%11.0%8.0%10.0%8.0%
Total Consolidated Revenue — Foreign exchange impact YoY (%)(%)
1.0%2.0%4.0%1.0%1.0%-1.0%-4.0%-1.0%-3.0%-3.0%-2.0%0.0%
Total Consolidated Revenue — Operational (constant-currency) growth YoY (%)(%)
-2.0%-2.0%-1.0%2.0%0.0%5.0%5.0%6.0%14.0%11.0%12.0%8.0%
Total Consolidated Revenue — Divestitures impact YoY (%)(%)
-1.0%-1.0%-1.0%-2.0%-4.0%-3.0%-4.0%
Total Consolidated Revenue — Organic operational growth YoY (%)(%)
-1.0%-1.0%0.0%4.0%4.0%8.0%9.0%6.0%14.0%11.0%12.0%8.0%
U.S. Operating Segment Revenue ($M)($M)7
1,2461,2661,0901,2361,3221,3561,1831,2571,3461,3081,1631,211
U.S. Companion Animal Revenue ($M)($M)5
9801,0448651,0021,0691,1769731,0081,0681,080898941
U.S. Companion Animal Revenue — Reported growth YoY (%)(%)
-8.0%-11.0%-11.0%-1.0%0.0%9.0%8.0%7.0%18.0%13.0%25.0%10.0%
U.S. Companion Animal Revenue — Foreign exchange impact YoY (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
U.S. Companion Animal Revenue — Operational (constant-currency) growth YoY (%)(%)
-8.0%-11.0%-11.0%-1.0%0.0%9.0%8.0%7.0%18.0%13.0%25.0%10.0%
U.S. Companion Animal Revenue — Divestitures impact YoY (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%
U.S. Companion Animal Revenue — Organic operational growth YoY (%)(%)
-8.0%-11.0%-11.0%-1.0%0.0%9.0%8.0%7.0%18.0%13.0%25.0%10.0%
U.S. Livestock Revenue ($M)($M)5
266222225234253180210249278228265270
U.S. Livestock Revenue — Reported growth YoY (%)(%)
5.0%23.0%7.0%-6.0%-9.0%-21.0%-21.0%-8.0%5.0%11.0%-7.0%4.0%
U.S. Livestock Revenue — Foreign exchange impact YoY (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
U.S. Livestock Revenue — Operational (constant-currency) growth YoY (%)(%)
5.0%23.0%7.0%-6.0%-9.0%-21.0%-21.0%-8.0%5.0%11.0%-7.0%4.0%
U.S. Livestock Revenue — Divestitures impact YoY (%)(%)
0.0%0.0%0.0%-9.0%-23.0%-19.0%-19.0%
U.S. Livestock Revenue — Organic operational growth YoY (%)(%)
5.0%23.0%7.0%3.0%14.0%-2.0%-2.0%-8.0%5.0%11.0%-7.0%4.0%
U.S. Operating Segment Revenue — Reported growth YoY (%)(%)
-6.0%-7.0%-8.0%-2.0%-2.0%4.0%2.0%4.0%15.0%12.0%16.0%9.0%
U.S. Operating Segment Revenue — Foreign exchange impact YoY (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
U.S. Operating Segment Revenue — Operational (constant-currency) growth YoY (%)(%)
-6.0%-7.0%-8.0%-2.0%-2.0%4.0%2.0%4.0%15.0%12.0%16.0%9.0%
U.S. Operating Segment Revenue — Divestitures impact YoY (%)(%)
0.0%0.0%0.0%-2.0%-5.0%-3.0%-4.0%
U.S. Operating Segment Revenue — Organic operational growth YoY (%)(%)
-6.0%-7.0%-8.0%0.0%3.0%7.0%6.0%4.0%15.0%12.0%16.0%9.0%
International Operating Segment Revenue ($M)($M)7
1,1161,1731,1491,1211,0551,0701,0081,0391,0211,0351,007982
International Companion Animal Revenue ($M)($M)5
585664654599583612573562541569552507
International Companion Animal Revenue — Reported growth YoY (%)(%)
1.0%8.0%15.0%7.0%8.0%8.0%4.0%11.0%7.0%7.0%10.0%13.0%
International Companion Animal Revenue — Foreign exchange impact YoY (%)(%)
1.0%3.0%8.0%3.0%4.0%0.0%-6.0%-2.0%-4.0%-5.0%-4.0%3.0%
International Companion Animal Revenue — Operational (constant-currency) growth YoY (%)(%)
0.0%5.0%7.0%4.0%4.0%8.0%10.0%13.0%11.0%12.0%14.0%10.0%
International Companion Animal Revenue — Divestitures impact YoY (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%
International Companion Animal Revenue — Organic operational growth YoY (%)(%)
0.0%5.0%7.0%4.0%4.0%8.0%10.0%13.0%11.0%12.0%14.0%10.0%
International Livestock Revenue ($M)($M)5
531509495522472458435477480466455475
International Livestock Revenue — Reported growth YoY (%)(%)
8.0%8.0%19.0%9.0%-2.0%-2.0%-4.0%0.0%7.0%0.0%-4.0%5.0%
International Livestock Revenue — Foreign exchange impact YoY (%)(%)
2.0%4.0%7.0%2.0%1.0%-3.0%-8.0%-6.0%-8.0%-8.0%-6.0%-2.0%
International Livestock Revenue — Operational (constant-currency) growth YoY (%)(%)
6.0%4.0%12.0%7.0%-3.0%1.0%4.0%6.0%15.0%8.0%2.0%7.0%
International Livestock Revenue — Divestitures impact YoY (%)(%)
-3.0%-2.0%-2.0%-5.0%-11.0%-9.0%-8.0%
International Livestock Revenue — Organic operational growth YoY (%)(%)
9.0%6.0%14.0%12.0%8.0%10.0%12.0%6.0%15.0%8.0%2.0%7.0%
International Operating Segment Revenue — Reported growth YoY (%)(%)
4.0%8.0%17.0%8.0%3.0%3.0%0.0%6.0%7.0%4.0%3.0%9.0%
International Operating Segment Revenue — Foreign exchange impact YoY (%)(%)
1.0%3.0%8.0%3.0%2.0%-2.0%-7.0%-4.0%-6.0%-6.0%-5.0%1.0%
International Operating Segment Revenue — Operational (constant-currency) growth YoY (%)(%)
3.0%5.0%9.0%5.0%1.0%5.0%7.0%10.0%13.0%10.0%8.0%8.0%
International Operating Segment Revenue — Divestitures impact YoY (%)(%)
-1.0%-1.0%-1.0%-2.0%-5.0%-4.0%-4.0%
International Operating Segment Revenue — Organic operational growth YoY (%)(%)
4.0%6.0%10.0%7.0%6.0%9.0%11.0%10.0%13.0%10.0%8.0%8.0%
Total Companion Animal Revenue ($M)($M)7
1,5651,7081,5191,6011,6521,7881,5461,5701,6091,6491,4501,448
Dogs and Cats Revenue ($M)($M)4
1,4921,6341,4431,5001,5861,7161,4811,4771,5511,5811,3841,360
Dogs and Cats Revenue — Reported growth YoY (%)(%)
-6.0%-5.0%-2.0%2.0%2.0%9.0%7.0%9.0%15.0%11.0%20.0%11.0%
Dogs and Cats Revenue — Foreign exchange impact YoY (%)(%)
0.0%1.0%3.0%1.0%1.0%0.0%-2.0%0.0%-1.0%-2.0%-2.0%1.0%
Dogs and Cats Revenue — Operational (constant-currency) growth YoY (%)(%)
-6.0%-6.0%-5.0%1.0%1.0%9.0%9.0%9.0%16.0%13.0%22.0%10.0%
Dogs and Cats Revenue — Organic operational growth YoY (%)(%)
-6.0%-6.0%-5.0%1.0%1.0%9.0%9.0%9.0%16.0%13.0%22.0%10.0%
Horses (Equine) Revenue ($M)($M)4
7374761016672659358686688
Horses (Equine) Revenue — Reported growth YoY (%)(%)
6.0%4.0%19.0%9.0%14.0%6.0%-2.0%6.0%-3.0%5.0%-8.0%11.0%
Horses (Equine) Revenue — Foreign exchange impact YoY (%)(%)
0.0%1.0%6.0%3.0%0.0%0.0%-4.0%-1.0%-2.0%-1.0%-2.0%0.0%
Horses (Equine) Revenue — Operational (constant-currency) growth YoY (%)(%)
6.0%3.0%13.0%6.0%14.0%6.0%2.0%7.0%-1.0%6.0%-6.0%11.0%
Horses (Equine) Revenue — Organic operational growth YoY (%)(%)
6.0%3.0%13.0%6.0%14.0%6.0%2.0%7.0%-1.0%6.0%-6.0%11.0%
Total Companion Animal Revenue — Reported growth YoY (%)(%)
-5.0%-5.0%-1.0%2.0%3.0%8.0%7.0%8.0%14.0%11.0%18.0%11.0%
Total Companion Animal Revenue — Foreign exchange impact YoY (%)(%)
0.0%1.0%3.0%1.0%1.0%0.0%-2.0%-1.0%-1.0%-1.0%-2.0%1.0%
Total Companion Animal Revenue — Operational (constant-currency) growth YoY (%)(%)
-5.0%-6.0%-4.0%1.0%2.0%8.0%9.0%9.0%15.0%12.0%20.0%10.0%
Total Companion Animal Revenue — Divestitures impact YoY (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Companion Animal Revenue — Organic operational growth YoY (%)(%)
-5.0%-6.0%-4.0%1.0%2.0%8.0%9.0%9.0%15.0%12.0%20.0%10.0%
Total Livestock Revenue ($M)($M)10
797731720756725638645726758694720745
Cattle (Beef & Dairy) Revenue ($M)($M)4
439390392415399320358399391350391401
Cattle (Beef & Dairy) Revenue — Reported growth YoY (%)(%)
6.0%21.0%15.0%4.0%2.0%-9.0%-8.0%0.0%5.0%6.0%-2.0%6.0%
Cattle (Beef & Dairy) Revenue — Foreign exchange impact YoY (%)(%)
1.0%3.0%4.0%1.0%0.0%-3.0%-5.0%-4.0%-4.0%-6.0%-3.0%-1.0%
Cattle (Beef & Dairy) Revenue — Operational (constant-currency) growth YoY (%)(%)
5.0%18.0%11.0%3.0%2.0%-6.0%-3.0%4.0%9.0%12.0%1.0%7.0%
Cattle (Beef & Dairy) Revenue — Organic operational growth YoY (%)(%)
5.0%18.0%11.0%3.0%2.0%-6.0%-3.0%4.0%9.0%12.0%1.0%7.0%
Swine Revenue ($M)($M)4
120117123125111119111128131130127139
Swine Revenue — Reported growth YoY (%)(%)
3.0%-1.0%17.0%-2.0%-15.0%-8.0%-13.0%-8.0%2.0%-2.0%-11.0%1.0%
Swine Revenue — Foreign exchange impact YoY (%)(%)
1.0%2.0%6.0%2.0%2.0%-1.0%-6.0%-4.0%-7.0%-7.0%-4.0%1.0%
Swine Revenue — Operational (constant-currency) growth YoY (%)(%)
2.0%-3.0%11.0%-4.0%-17.0%-7.0%-7.0%-4.0%9.0%5.0%-7.0%0.0%
Swine Revenue — Organic operational growth YoY (%)(%)
2.0%-3.0%11.0%-4.0%-17.0%-7.0%-7.0%-4.0%9.0%5.0%-7.0%0.0%
Poultry Revenue ($M)($M)4
108115118117106103106117139132139127
Poultry Revenue — Reported growth YoY (%)(%)
2.0%11.0%11.0%0.0%-24.0%-22.0%-24.0%-8.0%9.0%1.0%0.0%10.0%
Poultry Revenue — Foreign exchange impact YoY (%)(%)
-1.0%1.0%3.0%1.0%1.0%-1.0%-4.0%-4.0%-7.0%-6.0%-6.0%-3.0%
Poultry Revenue — Operational (constant-currency) growth YoY (%)(%)
3.0%10.0%8.0%-1.0%-25.0%-21.0%-20.0%-4.0%16.0%7.0%6.0%13.0%
Poultry Revenue — Organic operational growth YoY (%)(%)
3.0%10.0%8.0%-1.0%-25.0%-21.0%-20.0%-4.0%16.0%7.0%6.0%13.0%
Fish (Aquaculture) Revenue ($M)($M)4
988366817874536570624562
Fish (Aquaculture) Revenue — Reported growth YoY (%)(%)
23.0%2.0%20.0%25.0%11.0%19.0%18.0%5.0%23.0%19.0%-8.0%2.0%
Fish (Aquaculture) Revenue — Foreign exchange impact YoY (%)(%)
5.0%4.0%9.0%5.0%3.0%1.0%-3.0%1.0%-3.0%-1.0%-2.0%-3.0%
Fish (Aquaculture) Revenue — Operational (constant-currency) growth YoY (%)(%)
18.0%-2.0%11.0%20.0%8.0%18.0%21.0%4.0%26.0%20.0%-6.0%5.0%
Fish (Aquaculture) Revenue — Organic operational growth YoY (%)(%)
18.0%-2.0%11.0%20.0%8.0%18.0%21.0%4.0%26.0%20.0%-6.0%5.0%
Sheep and Other Livestock Revenue ($M)($M)4
322621183122171727201816
Sheep and Other Livestock Revenue — Reported growth YoY (%)(%)
10.0%4.0%5.0%6.0%15.0%10.0%-6.0%6.0%-7.0%-23.0%-38.0%-16.0%
Sheep and Other Livestock Revenue — Foreign exchange impact YoY (%)(%)
4.0%8.0%7.0%-3.0%-3.0%1.0%-6.0%-1.0%-1.0%-2.0%-5.0%1.0%
Sheep and Other Livestock Revenue — Operational (constant-currency) growth YoY (%)(%)
6.0%-4.0%-2.0%9.0%18.0%9.0%0.0%7.0%-6.0%-21.0%-33.0%-17.0%
Sheep and Other Livestock Revenue — Organic operational growth YoY (%)(%)
6.0%-4.0%-2.0%9.0%18.0%9.0%0.0%7.0%-6.0%-21.0%-33.0%-17.0%
Total Livestock Revenue — Reported growth YoY (%)(%)
7.0%12.0%15.0%4.0%-4.0%-8.0%-10.0%-3.0%6.0%3.0%-5.0%5.0%
Total Livestock Revenue — Foreign exchange impact YoY (%)(%)
1.0%2.0%5.0%1.0%1.0%-2.0%-5.0%-4.0%-5.0%-6.0%-4.0%-1.0%
Total Livestock Revenue — Operational (constant-currency) growth YoY (%)(%)
6.0%10.0%10.0%3.0%-5.0%-6.0%-5.0%1.0%11.0%9.0%-1.0%6.0%
Total Livestock Revenue — Divestitures impact YoY (%)(%)
-1.0%-1.0%-2.0%-6.0%-15.0%-12.0%-12.0%
Total Livestock Revenue — Organic operational growth YoY (%)(%)
7.0%11.0%12.0%9.0%10.0%6.0%7.0%1.0%11.0%9.0%-1.0%6.0%
Product & Service Revenue by Veterinary Product Category ($M)($M)
2,3622,4392,2392,3572,3962,4412,1682,2962,3672,3432,1702,193
Key Dermatology Portfolio (Apoquel, Apoquel Chewable & Cytopoint) — Global Revenue ($M)($M)3
396395347469460387417449414360375
Key Dermatology Portfolio — Global operational growth YoY (%)(%)
-16.0%-16.0%-11.0%3.0%11.0%10.0%11.0%16.0%25.0%7.0%
Key Dermatology Portfolio — U.S. Revenue ($M)($M)1
266251215272306307249270303
Key Dermatology Portfolio — U.S. operational growth YoY (%)(%)
-13.0%-18.0%-13.0%1.0%1.0%9.0%7.0%7.0%17.0%
Key Dermatology Portfolio — International Revenue ($M)($M)1
130144131155162153138147146131127123
Key Dermatology Portfolio — International operational growth YoY (%)(%)
-20.0%-13.0%-5.0%2.0%7.0%15.0%15.0%19.0%13.0%19.0%23.0%10.0%
Simparica Franchise (Simparica & Simparica Trio) — Global Revenue ($M)($M)3
358442385333356448367324333384
Simparica Franchise — Global operational growth YoY (%)(%)
1.0%0.0%-1.0%3.0%7.0%17.0%19.0%21.0%27.0%
Simparica Franchise — U.S. Revenue ($M)($M)1
259308238263329240237
Simparica Franchise — U.S. operational growth YoY (%)(%)
-2.0%-6.0%-8.0%2.0%18.0%17.0%
Simparica Franchise — International Revenue ($M)($M)2
9913414790931191068475
Simparica Franchise — International operational growth YoY (%)(%)
10.0%19.0%14.0%6.0%22.0%16.0%23.0%32.0%28.0%
Simparica Trio — International Revenue ($M)($M)
67764141553131
Osteoarthritis (OA) Pain mAbs Franchise (Librela/Lenivia & Solensia/Portela) — Global Revenue ($M)($M)3
137147140137138147150149131124
OA Pain mAbs Franchise — Global operational growth YoY (%)(%)
2.0%-3.0%-8.0%-11.0%-11.0%15.0%20.0%
OA Pain mAbs Franchise — U.S. Revenue ($M)($M)3
51515553626571737157
OA Pain mAbs Franchise — U.S. operational growth YoY (%)(%)
-12.0%-18.0%-15.0%-25.0%-12.0%14.0%22.0%
Canine OA Pain mAbs (Librela) — U.S. Revenue ($M)($M)
3437364145475355534044
Feline OA Pain mAbs (Solensia) — U.S. Revenue ($M)($M)
171817171718181814
OA Pain mAbs Franchise — International Revenue ($M)($M)3
8696858480838279787974
OA Pain mAbs Franchise — International operational growth YoY (%)(%)
13.0%7.0%-2.0%2.0%-3.0%4.0%16.0%18.0%27.0%35.0%67.0%
Canine OA Pain mAbs (Librela & Lenivia) — International Revenue ($M)($M)
7164646264656262635953
Feline OA Pain mAbs (Solensia & Portela) — International Revenue ($M)($M)
2421211819181716161513
Top 10 Selling Product Lines Share of Total Revenue (%)2
Major Veterinary Product Categories (categories)
777777778887
Major Animal Species Covered (species)
888888888888
Total Product & Service Revenue by Geographic Market ($M)($M)2
2,3622,4392,2392,3572,3962,4412,1682,2962,3672,3432,1702,193
United States Revenue ($M)($M)5
1,2461,2661,0901,2361,3221,3561,1831,2571,3461,3081,1631,211
United States Revenue — Reported growth YoY (%)(%)
-6.0%-7.0%-8.0%-2.0%-2.0%4.0%2.0%4.0%15.0%12.0%16.0%9.0%
United States Revenue — Foreign exchange impact YoY (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
United States Revenue — Operational (constant-currency) growth YoY (%)(%)
-6.0%-7.0%-8.0%-2.0%-2.0%4.0%2.0%4.0%15.0%12.0%16.0%9.0%
United States Revenue — Divestitures impact YoY (%)(%)
0.0%0.0%0.0%-2.0%-5.0%-3.0%-4.0%
United States Revenue — Organic operational growth YoY (%)(%)
-6.0%-7.0%-8.0%0.0%3.0%7.0%6.0%4.0%15.0%12.0%16.0%9.0%
Total International Markets Revenue ($M)($M)17
1,1161,1731,1491,1211,0551,0701,0081,0391,0211,0351,007982
Brazil ($M)($M)3
11410390112100938811310199101117
Brazil — Reported growth YoY (%)(%)
9.0%11.0%11.0%-1.0%-1.0%-6.0%-13.0%-3.0%0.0%9.0%20.0%22.0%
Brazil — Foreign exchange impact YoY (%)(%)
6.0%11.0%12.0%5.0%0.0%-11.0%-19.0%-13.0%-14.0%-1.0%7.0%7.0%
Brazil — Organic operational growth YoY (%)(%)
3.0%0.0%-1.0%-6.0%-1.0%5.0%6.0%10.0%14.0%10.0%13.0%15.0%
Australia ($M)($M)3
1049489848783758083837375
Australia — Reported growth YoY (%)(%)
13.0%13.0%13.0%5.0%5.0%0.0%3.0%7.0%-1.0%1.0%-11.0%17.0%
Australia — Foreign exchange impact YoY (%)(%)
9.0%11.0%11.0%-3.0%-1.0%-4.0%-5.0%5.0%0.0%-1.0%-4.0%-2.0%
Australia — Organic operational growth YoY (%)(%)
4.0%2.0%2.0%8.0%6.0%4.0%8.0%2.0%-1.0%2.0%-7.0%19.0%
United Kingdom ($M)($M)3
757278898277778480737767.9
United Kingdom — Reported growth YoY (%)(%)
-5.0%-11.0%5.0%6.0%3.0%5.0%0.0%24.0%3.0%16.0%13.0%13.0%
United Kingdom — Foreign exchange impact YoY (%)(%)
1.0%-1.0%7.0%3.0%5.0%4.0%-1.0%7.0%1.0%3.0%4.0%9.0%
United Kingdom — Organic operational growth YoY (%)(%)
-4.0%-9.0%-2.0%3.0%-2.0%1.0%1.0%17.0%2.0%13.0%9.0%4.0%
Canada ($M)($M)3
707273807073677566756171.1
Canada — Reported growth YoY (%)(%)
-8.0%1.0%4.0%7.0%6.0%-3.0%10.0%4.0%5.0%7.0%22.0%9.0%
Canada — Foreign exchange impact YoY (%)(%)
0.0%0.0%4.0%-2.0%0.0%-3.0%-7.0%-1.0%-3.0%-1.0%1.0%-2.0%
Canada — Organic operational growth YoY (%)(%)
2.0%6.0%0.0%9.0%6.0%0.0%17.0%5.0%8.0%8.0%21.0%11.0%
Germany ($M)($M)3
516959656258515957585154.1
Germany — Reported growth YoY (%)(%)
-18.0%21.0%7.0%10.0%9.0%0.0%0.0%9.0%14.0%9.0%13.0%23.0%
Germany — Foreign exchange impact YoY (%)(%)
-2.0%2.0%11.0%6.0%8.0%1.0%-4.0%2.0%1.0%-1.0%1.0%8.0%
Germany — Organic operational growth YoY (%)(%)
-15.0%19.0%-4.0%4.0%1.0%-1.0%4.0%7.0%13.0%10.0%12.0%15.0%
China ($M)($M)3
616263504572606561687664.7
China — Reported growth YoY (%)(%)
20.0%-7.0%15.0%-23.0%-26.0%6.0%-21.0%0.0%-12.0%-19.0%-25.0%-29.0%
China — Foreign exchange impact YoY (%)(%)
6.0%7.0%5.0%0.0%0.0%0.0%-1.0%1.0%0.0%-3.0%-3.0%-1.0%
China — Organic operational growth YoY (%)(%)
14.0%-14.0%10.0%-23.0%-26.0%6.0%-20.0%-1.0%-12.0%-16.0%-22.0%-28.0%
France ($M)($M)3
374037524033404536344140.5
France — Reported growth YoY (%)(%)
6.0%-5.0%-5.0%16.0%11.0%-3.0%-2.0%13.0%6.0%0.0%21.0%15.0%
France — Foreign exchange impact YoY (%)(%)
-3.0%3.0%9.0%8.0%6.0%3.0%-4.0%3.0%2.0%-2.0%1.0%8.0%
France — Organic operational growth YoY (%)(%)
10.0%-8.0%-14.0%8.0%5.0%-6.0%2.0%10.0%4.0%2.0%20.0%7.0%
Mexico ($M)($M)3
494748444138374039464443.3
Mexico — Reported growth YoY (%)(%)
17.0%21.0%37.0%10.0%5.0%-17.0%-16.0%-7.0%-7.0%21.0%13.0%22.0%
Mexico — Foreign exchange impact YoY (%)(%)
10.0%15.0%17.0%6.0%0.0%-17.0%-15.0%-11.0%-8.0%11.0%10.0%14.0%
Mexico — Organic operational growth YoY (%)(%)
7.0%6.0%20.0%4.0%5.0%0.0%-1.0%4.0%1.0%10.0%3.0%8.0%
Spain ($M)($M)3
374340373837333035333227.3
Spain — Reported growth YoY (%)(%)
3.0%8.0%38.0%23.0%9.0%12.0%3.0%7.0%17.0%6.0%-3.0%28.0%
Spain — Foreign exchange impact YoY (%)(%)
-2.0%2.0%16.0%8.0%6.0%4.0%-4.0%-1.0%3.0%-2.0%1.0%9.0%
Spain — Organic operational growth YoY (%)(%)
7.0%7.0%22.0%15.0%3.0%8.0%7.0%8.0%14.0%8.0%-4.0%19.0%
Italy ($M)($M)3
304039353538293431362833.9
Italy — Reported growth YoY (%)(%)
-12.0%8.0%30.0%3.0%13.0%6.0%4.0%0.0%19.0%3.0%8.0%32.0%
Italy — Foreign exchange impact YoY (%)(%)
-2.0%1.0%16.0%7.0%7.0%4.0%-5.0%2.0%-3.0%1.0%2.0%9.0%
Italy — Organic operational growth YoY (%)(%)
-10.0%7.0%14.0%-4.0%6.0%2.0%9.0%-2.0%22.0%2.0%6.0%23.0%
Chile ($M)($M)3
343438402936343031313131.4
Chile — Reported growth YoY (%)(%)
3.0%0.0%9.0%33.0%-6.0%16.0%10.0%-3.0%0.0%-21.0%-21.0%-10.0%
Chile — Foreign exchange impact YoY (%)(%)
-2.0%0.0%6.0%3.0%-2.0%-3.0%-1.0%-2.0%-6.0%-4.0%-4.0%1.0%
Chile — Organic operational growth YoY (%)(%)
5.0%0.0%3.0%30.0%-4.0%19.0%11.0%-1.0%6.0%-17.0%-17.0%-11.0%
Japan ($M)($M)3
264135393445363833393738
Japan — Reported growth YoY (%)(%)
-24.0%-5.0%9.0%3.0%3.0%15.0%-3.0%0.0%-3.0%-17.0%-5.0%5.0%
Japan — Foreign exchange impact YoY (%)(%)
-6.0%-11.0%-4.0%-1.0%5.0%5.0%-5.0%1.0%-6.0%-13.0%-9.0%-4.0%
Japan — Organic operational growth YoY (%)(%)
-18.0%6.0%13.0%4.0%-2.0%10.0%2.0%-1.0%3.0%-4.0%4.0%9.0%
Other Developed Markets ($M)($M)3
183187169182164162133151148138127138
Other Developed Markets — Reported growth YoY (%)(%)
11.0%7.0%27.0%21.0%11.0%17.0%5.0%9.0%17.0%10.0%4.0%21.0%
Other Developed Markets — Foreign exchange impact YoY (%)(%)
1.0%3.0%11.0%6.0%6.0%2.0%-6.0%1.0%-1.0%-2.0%0.0%4.0%
Other Developed Markets — Organic operational growth YoY (%)(%)
10.0%4.0%16.0%15.0%5.0%15.0%11.0%8.0%18.0%12.0%4.0%17.0%
Other Emerging Markets ($M)($M)3
245269291212228225248195220222228179
Other Emerging Markets — Reported growth YoY (%)(%)
7.0%21.0%22.0%9.0%4.0%1.0%9.0%9.0%18.0%9.0%6.0%1.0%
Other Emerging Markets — Foreign exchange impact YoY (%)(%)
-2.0%1.0%3.0%0.0%0.0%-1.0%-8.0%-17.0%-19.0%-25.0%-25.0%-13.0%
Other Emerging Markets — Organic operational growth YoY (%)(%)
10.0%21.0%19.0%9.0%4.0%2.0%17.0%26.0%37.0%34.0%31.0%14.0%
Total International Markets Revenue — Reported growth YoY (%)(%)
4.0%8.0%17.0%8.0%3.0%3.0%0.0%6.0%7.0%4.0%3.0%9.0%
Total International Markets Revenue — Foreign exchange impact YoY (%)(%)
1.0%3.0%8.0%3.0%2.0%-2.0%-7.0%-4.0%-6.0%-6.0%-5.0%1.0%
Total International Markets Revenue — Organic operational growth YoY (%)(%)
4.0%6.0%9.0%5.0%1.0%5.0%7.0%10.0%13.0%10.0%8.0%8.0%
Property, Plant and Equipment, Net by Geographic Region ($M)($M)1
3,7823,7563,7193,6933,6003,5373,4413,3913,2983,2003,2513,204
Countries Where Zoetis Products Are Marketed (countries)
100100100100100100100100100100100100
Total Reportable Operating Segments Earnings ($M)($M)6
1,4301,4981,3361,4041,4551,5131,3301,3421,4311,3901,2911,260
Total Reportable Segments Earnings — Reported growth YoY (%)(%)
-2.0%-2.0%2.0%5.0%2.0%9.0%3.0%7.0%16.0%11.0%12.0%6.0%
Total Reportable Segments Earnings — Foreign exchange impact YoY (%)(%)
1.0%1.0%2.0%2.0%1.0%2.0%-2.0%-1.0%-2.0%-4.0%-4.0%0.0%
Total Reportable Segments Earnings — Operational growth YoY (%)(%)
-3.0%-3.0%0.0%3.0%1.0%7.0%5.0%8.0%18.0%15.0%16.0%6.0%
Total Reportable Segments Depreciation & Amortization ($M)($M)
504949495048464345464747
U.S. Operating Segment Earnings ($M)($M)7
830837697830899930779819889872756766
U.S. Segment Earnings — Reported growth YoY (%)(%)
-8.0%-10.0%-11.0%1.0%1.0%7.0%3.0%7.0%19.0%18.0%23.0%6.0%
U.S. Segment Earnings — Operational growth YoY (%)(%)
-8.0%-10.0%-11.0%1.0%1.0%7.0%3.0%7.0%19.0%18.0%23.0%6.0%
U.S. Segment Revenue ($M)($M)
1,2461,2661,0901,2361,3221,3561,1831,2571,3461,3081,1631,211
U.S. Segment Cost of Sales ($M)($M)1
222214194213222208199229258232217255
U.S. Cost of Sales — Reported growth YoY (%)(%)
0.0%3.0%-3.0%-7.0%-14.0%-10.0%-8.0%-10.0%13.0%8.0%7.0%18.0%
U.S. Segment Gross Profit ($M)($M)2
1,0241,0528961,0231,1001,1489841,0281,0881,076946956
U.S. Gross Profit — Reported growth YoY (%)(%)
-7.0%-8.0%-9.0%0.0%1.0%7.0%4.0%8.0%15.0%13.0%18.0%7.0%
U.S. Segment Gross Margin (%)(%)
82.2%83.1%82.2%82.8%83.2%84.7%83.2%81.8%80.8%82.3%81.3%78.9%
U.S. Segment Operating Expenses ($M)($M)1
194215199193201218205212199204190184
U.S. Operating Expenses — Reported growth YoY (%)(%)
-3.0%-1.0%-3.0%-9.0%1.0%7.0%8.0%15.0%-1.0%-4.0%1.0%-2.0%
U.S. Segment Depreciation & Amortization ($M)($M)
242423232522232020212422
International Operating Segment Earnings ($M)($M)8
600661639574556583551523542518535494
International Segment Earnings — Reported growth YoY (%)(%)
7.0%12.0%21.0%10.0%3.0%13.0%3.0%6.0%10.0%1.0%0.0%5.0%
International Segment Earnings — Foreign exchange impact YoY (%)(%)
2.0%4.0%6.0%4.0%3.0%5.0%-4.0%-4.0%-5.0%-10.0%-9.0%0.0%
International Segment Earnings — Operational growth YoY (%)(%)
5.0%8.0%15.0%6.0%0.0%8.0%7.0%10.0%15.0%11.0%9.0%5.0%
International Segment Revenue ($M)($M)
1,1161,1731,1491,1211,0551,0701,0081,0391,0211,0351,007982
International Segment Cost of Sales ($M)($M)2
347340334365331314302336321342313322
International Cost of Sales — Reported growth YoY (%)(%)
1.0%6.0%13.0%9.0%3.0%-8.0%-4.0%4.0%5.0%9.0%8.0%18.0%
International Cost of Sales — Operational growth YoY (%)(%)
1.0%2.0%3.0%8.0%2.0%1.0%10.0%7.0%13.0%9.0%7.0%17.0%
International Segment Gross Profit ($M)($M)3
769833815756724756706703700693694660
International Gross Profit — Reported growth YoY (%)(%)
5.0%9.0%18.0%8.0%3.0%9.0%2.0%7.0%8.0%2.0%1.0%5.0%
International Gross Profit — Operational growth YoY (%)(%)
3.0%6.0%11.0%4.0%1.0%7.0%6.0%11.0%13.0%11.0%8.0%5.0%
International Segment Gross Margin (%)(%)
68.9%71.0%70.9%67.4%68.6%70.7%70.0%67.7%68.6%67.0%68.9%67.2%
International Segment Operating Expenses ($M)($M)2
169172175183167173154180157175159165
International Operating Expenses — Reported growth YoY (%)(%)
0.0%1.0%7.0%2.0%6.0%-1.0%-3.0%9.0%1.0%5.0%5.0%6.0%
International Operating Expenses — Operational growth YoY (%)(%)
-1.0%-2.0%0.0%-1.0%3.0%2.0%4.0%13.0%7.0%9.0%8.0%5.0%
International Segment Depreciation & Amortization ($M)($M)
262526262526232325252325
Consolidated Income Before Provision for Taxes on Income ($M)($M)6
729866758761887902810732874780747650
Other Business Activities (Centralized R&D & Contract Manufacturing Net Loss) ($M)($M)
-134-135-141-159-140-134-129-151-137-142-132-142
Reconciling Item — Corporate Expenses & Net Interest ($M)($M)1
-303-315-315-342-306-321-271-320-306-299-288-320
Corporate Depreciation & Amortization ($M)($M)
232625262629293231333233
Reconciling Item — Purchase Accounting Adjustments ($M)($M)1
-31-30-28-31-32-33-32-33-35-35-37-35
Unallocated Purchase Accounting Intangible Amortization & Depreciation ($M)($M)
313131313233323435353737
Reconciling Item — Acquisition and Divestiture-Related Costs ($M)($M)1
-2-2-2-10-10-6-7-50-1
Acquisition & Divestiture-Related Depreciation & Amortization ($M)($M)
00000000000
Reconciling Item — Certain Significant Items ($M)($M)1
-133-81-27-22-7-47-6-2-1-70-6-12
Certain Significant Items Depreciation & Amortization ($M)($M)
000000000000
Reconciling Item — Other Unallocated Global Manufacturing & Supply Overhead ($M)($M)1
-98-69-65-88-83-75-82-98-71-59-81-100
Other Unallocated Manufacturing Depreciation & Amortization ($M)($M)
111211111212
Non-GAAP Adjusted Net Income Attributable to Zoetis ($M)($M)13
720781646648754791633632716711634569
Adjusted Net Income — Reported growth YoY (%)(%)
-5.0%-1.0%2.0%3.0%5.0%10.0%4.0%11.0%14.0%9.0%4.0%6.0%
Adjusted Net Income — Foreign exchange impact YoY (%)(%)
2.0%1.0%1.0%1.0%0.0%3.0%2.0%2.0%-1.0%-9.0%-11.0%0.0%
Adjusted Net Income — Operational growth YoY (%)(%)
-7.0%-2.0%1.0%2.0%5.0%7.0%2.0%9.0%15.0%18.0%15.0%6.0%
Adjusted Net Income — Divestitures impact YoY (%)(%)
0.0%0.0%0.0%-2.0%-4.0%-3.0%-4.0%
Adjusted Net Income — Organic operational growth YoY (%)(%)
-7.0%-2.0%1.0%4.0%9.0%10.0%6.0%9.0%15.0%18.0%15.0%6.0%
Non-GAAP Adjusted Diluted Earnings per Common Share ($/sh)($)
1.751.871.531.481.701.781.411.401.581.561.381.24
Non-GAAP Adjusted Income Before Provision for Taxes ($M)($M)
895979815815926994811773917890790698
Non-GAAP Adjusted Provision for Taxes on Income ($M)($M)1
175198169167172203178141191179156131
Effective Tax Rate on Adjusted Pre-Tax Income (%)(%)
19.6%20.2%20.7%18.6%20.3%21.9%20.8%20.1%
Non-GAAP Adjusted Gross Profit ($M)($M)2
1,6971,7991,6241,6791,7271,8131,5811,6111,6891,6941,5481,486
Non-GAAP Adjusted Cost of Sales ($M)($M)
694669638708695661617706699667642727
Non-GAAP Adjusted Cost of Sales (% of Revenue)(%)
29.0%27.1%28.2%29.7%28.4%26.3%27.9%30.5%29.3%28.3%29.3%32.9%
Non-GAAP Adjusted SG&A Expenses ($M)($M)2
571586585615572603565619560578544562
Adjusted SG&A — Reported growth YoY (%)(%)
0.0%-3.0%4.0%-1.0%2.0%5.0%2.0%10.0%7.0%5.0%9.0%11.0%
Adjusted SG&A — Operational growth YoY (%)(%)
0.0%-4.0%1.0%-2.0%1.0%6.0%4.0%11.0%9.0%7.0%10.0%10.0%
Non-GAAP Adjusted R&D Expenses ($M)($M)2
174173179199174165162186166171161174
Adjusted R&D — Reported growth YoY (%)(%)
0.0%5.0%10.0%7.0%2.0%0.0%-2.0%7.0%10.0%17.0%13.0%18.0%
Adjusted R&D — Operational growth YoY (%)(%)
0.0%4.0%9.0%5.0%1.0%1.0%-2.0%7.0%10.0%17.0%13.0%17.0%
Non-GAAP Adjusted Amortization of Intangible Assets ($M)($M)
454454445455
Non-GAAP Adjusted Other (Income)/Deductions — Net ($M)($M)
-9-21-11-8-6-15-22-8-10-12
Non-GAAP Adjustment — Purchase Accounting Adjustments, Net of Tax ($M)($M)5
242421242425252627272929
Purchase Accounting Adjustments — Pre-Tax ($M)($M)
313028313233323335353735
Acquisition and Divestiture-Related Costs — Net of Tax ($M)($M)
221101055400
Acquisition and Divestiture-Related Costs — Pre-Tax ($M)($M)
222101067501
Certain Significant Items — Net of Tax ($M)($M)
103642320939620256615
Certain Significant Items — Pre-Tax ($M)($M)
13381272284862170612
Full-Year Financial Guidance — Revenue Range Low ($M)($M)11
9,2209,1209,6809,8259,4009,4509,4259,2259,2009,1009,0509,075
Full-Year Guidance — Revenue Range High ($M)($M)
9,3209,3209,96010,0259,4759,6009,5759,3759,3009,2509,2009,225
Full-Year Guidance — Adjusted Net Income Range Low ($M)($M)
2,6002,5702,8702,9752,8002,8252,7752,7002,6702,6402,6202,650
Full-Year Guidance — Adjusted Net Income Range High ($M)($M)
2,6402,6202,9503,0252,8402,8752,8252,7502,6952,6902,6702,700
Full-Year Guidance — Adjusted Diluted EPS Range Low ($/sh)($)
6.256.156.8576.306.306.2065.865.785.715.74
Full-Year Guidance — Adjusted Diluted EPS Range High ($/sh)($)
6.356.2577.106.406.406.306.105.925.885.815.84
Full-Year Guidance — Reported Diluted EPS Range Low ($/sh)($)
5.505.556.356.655.90
Full-Year Guidance — Reported Diluted EPS Range High ($/sh)($)
5.605.656.506.756
Full-Year Guidance — Adjusted SG&A Range Low ($M)($M)
2,3402,3302,3502,4302,3202,3552,3402,3002,2752,2252,1702,170
Full-Year Guidance — Adjusted SG&A Range High ($M)($M)
2,3702,3802,4002,4902,3602,4052,3902,3502,3252,2902,2202,220
Full-Year Guidance — Adjusted R&D Range Low ($M)($M)
705720735715690690690680665660665665
Full-Year Guidance — Adjusted R&D Range High ($M)($M)
715730745725700700700690675670675675
Accrued Sales Rebates and Revenue Deductions Liability [in Accrued Expenses] ($M)2
Contract Liabilities (Deferred Revenue) ($M)($M)
182121161819171821181311
Revenue Recognized from Beginning Contract Liability Balance ($M)($M)
1110-162301121
Total Inventories, Net ($M)($M)4
2,5362,5742,5502,4642,4652,4392,3652,3062,4162,4522,6512,564
Finished Goods Inventory ($M)($M)
1,1701,1471,0811,0941,0761,0419839961,0491,0501,1201,147
Work-in-Process Inventory ($M)($M)
1,0151,0691,1089911,0371,0271,0089339519531,051966
Raw Materials and Supplies Inventory ($M)($M)
351358361379352371374377416449480451
Inventory Write-Downs and Obsolescence Provision ($M)($M)
311313162016192629251733
Property, Plant and Equipment, Net ($M)($M)1
3,7823,7563,7193,6933,6003,5373,4413,3913,2983,2003,2513,204
Accumulated Depreciation ($M)($M)
3,1363,0663,0022,9352,8722,7962,6972,6352,6572,5902,6732,594
Total Goodwill ($M)($M)4
2,8882,7712,7782,7742,7642,7582,7162,7242,7442,7392,7592,759
U.S. Operating Segment Goodwill ($M)($M)
1,6221,5151,5151,5151,5151,5151,5151,5151,5151,5151,5321,532
International Operating Segment Goodwill ($M)($M)
1,2661,2561,2631,2591,2491,2431,2011,2091,2291,2241,2271,227
Goodwill, Gross ($M)($M)
3,4243,3073,3143,3103,3003,2943,2523,2603,2803,2753,2953,295
Accumulated Goodwill Impairment Loss ($M)($M)
536536536536536536536536536536536536
Identifiable Intangible Assets, Less Accumulated Amortization ($M)($M)3
8509189599981,0401,0751,0821,1271,1861,2261,2951,338
Finite-Lived Intangible Assets, Net ($M)($M)5
7127047457818248588759189721,0111,0591,102
Developed Technology Rights, Net ($M)($M)
495522557588626656678716767801847885
Finite-Lived Trademarks and Trade Names, Net ($M)($M)
104106109111114116119121125128134137
Other Finite-Lived Intangible Assets, Net ($M)($M)
1137679828486788180827880
Finite-Lived Intangible Assets, Gross ($M)($M)
2,6382,5862,6022,5952,5912,5782,5262,5362,5772,5702,6392,639
Finite-Lived Intangible Assets — Accumulated Amortization ($M)($M)
1,9261,8821,8571,8141,7671,7201,6511,6181,6051,5591,5801,537
Indefinite-Lived Intangible Assets (Excluding Goodwill) ($M)($M)3
138214214217216217207209214215236236
In-Process Research and Development (IPR&D) Assets ($M)($M)
65141141144144144135136141142141141
Indefinite-Lived Trademarks and Trade Names ($M)($M)
676767676667666666678888
Indefinite-Lived Product Rights ($M)($M)
666666677677
Amortization of Intangible Assets ($M)($M)1
393839383940404242424444
Intangible Asset Impairment Charges ($M)($M)
780005401118
Operating Lease Right-of-Use (ROU) Assets ($M)($M)3
269275282289292302220219223222225230
Operating Lease Liabilities — Noncurrent ($M)($M)
188190193197204210173174181181184188
Operating Cash Flows Used for Operating Leases ($M)($M)
151917112418161516151515
ROU Assets Obtained in Exchange for New Operating Lease Liabilities ($M)($M)
10710153517713188-1
Long-Term Debt, Net of Current Portion ($M)($M)6
8,2999,0489,0459,0427,0695,2315,2275,2206,5746,5636,5626,564
Current Portion of Long-Term Debt ($M)($M)
750001,3501,3501,3500
Revolving Credit Facility Maximum Borrowing Capacity ($M)($M)
464647511,75053515056556056
Long-Term Debt Maturities — Year 1 ($M)($M)
75075075000001,3501,3501,3501,3500
Long-Term Debt Maturities — Year 2 ($M)($M)
1,3501,3501,35075075075075000001,350
Long-Term Debt Maturities — Year 3 ($M)($M)
2,0002,0002,0001,3501,3505005007507507507500
Long-Term Debt Maturities — Year 4 ($M)($M)
7507507502,000000500500500500750
Cash Paid for Share Repurchases ($M)($M)8
500-3451,5352,060394338443553433533339235
Common Stock Repurchased — Aggregate Value ($M)($M)
5055586122,080381341447558427538342238
Common Stock Repurchased — Shares (M shares)(M)
6.706.2012.316.62.502.102.703.202.303.201.801.30
Treasury Stock Carrying Value ($M)($M)
12,34911,84511,28810,6858,6068,2267,8887,4456,8896,4645,9285,597
Common Stock Held in Treasury (M shares)(M)
94.487.781.577.060.458.055.953.450.348.144.943.5
Cash Dividends Declared ($M)($M)
-222021645202212244180196198370
Cash Dividends Paid ($M)($M)
219223224220222223224194197197198172
Dividends Payable ($M)($M)
022122423202222242240197198198
Stock-Based Compensation Expense ($M)($M)3
272625222222171918191817
SBC Grant Allocation — Restricted Stock Units (RSUs) & DSUs ($M)($M)
191916141413111110111010
SBC Grant Allocation — Performance-Vesting Share Units (PSUs) ($M)($M)
535556356555
SBC Grant Allocation — Stock Options ($M)($M)
344333332332
Restructuring Accrual Reserve — Total Ending Balance ($M)($M)4
939533251820202846552735
Restructuring Reserve — Current Liability ($M)($M)
919331231618182644532526
Restructuring Reserve — Noncurrent Liability ($M)($M)
222222222229
Restructuring Charges and Certain Acquisition/Divestiture Costs ($M)($M)
417520164-3-237118
Restructuring Reserve Utilized / Cash Payments ($M)($M)
32131256781579127
GAAP Effective Income Tax Rate (%)(%)2
1,890.0%2,020.0%2,070.0%1,860.0%2,040.0%2,210.0%2,080.0%2,000.0%1,980.0%
Deferred Tax Assets, Net of Valuation Allowance ($M)($M)
608617591636587617530540409366232206
Gross Unrecognized Tax Benefits (UTB) ($M)($M)
228226223222220219215213217214212209
U.S. Personal Consumption Expenditures: Pharmaceutical & Other Medical Products — SAAR ($B)
3,858.703,790.303,699.903,667.003,614.803,529.803,464.703,417.803,358.203,288.203,244.403,159.40
Income Statement — Revenue ($M)($M)14
2,3912,4682,2622,3732,4222,4742,1982,3172,3882,3612,1902,213
Cost of sales ($M)($M)
698673641687697664618707701668643728
Selling, general and administrative expenses ($M)($M)
582592588608582614574625565581547565
Research and development expenses ($M)($M)
174173180195175166162186167171162174
Restructuring charges and certain acquisition-related costs ($M)($M)
417520164-3-237118
Interest expense, net of capitalized interest ($M)($M)
626162575853545157595859
Other (income)/deductions — net ($M)($M)
-725201112-2152016-2588
Income before provision for taxes on income ($M)($M)
729866758789886912773732874780747650
Provision for taxes on income ($M)($M)
138175157165165186171151182156148127
Net income attributable to Zoetis Inc. ($M)($M)
591691601624721726602581682624599525
Earnings per share — Basic ($/sh)($)
1.441.651.421.631.631.341.511.371.31
Earnings per share — Diluted ($/sh)($)
1.441.651.421.631.631.341.501.371.31
Weighted-average basic shares outstanding (M)(M)
412418422443445448453456458
Weighted-average diluted shares outstanding (M)(M)
412418422443446448454456459
Dividends declared per common share ($/sh)($)
00.530.531.0300.500.500.9300.430.430.81
Balance Sheet — Total assets ($M)($M)14
15,08815,07715,15415,49015,15914,47914,09814,23714,35714,16514,34814,286
Cash and cash equivalents ($M)($M)
1,3331,4761,9412,4502,2701,6321,7822,1141,7141,5741,9752,041
Accounts receivable, less allowance for doubtful accounts ($M)($M)
1,6921,5711,5061,4091,5411,5401,3611,3161,4111,3831,2931,304
Inventories ($M)($M)
2,5362,5742,5502,4642,4652,4392,3652,3062,4162,4522,6512,564
Total current assets ($M)($M)
6,2936,3566,4746,7736,5835,9235,8775,9866,2826,2026,3596,343
Property, plant and equipment, less accumulated depreciation ($M)($M)
3,7823,7563,7193,6933,6003,5373,4413,3913,2983,2003,2513,204
Operating lease right-of-use assets ($M)($M)
269275282289292302220219223222225230
Goodwill ($M)($M)
2,8882,7712,7782,7742,7642,7582,7162,7242,7442,7392,7592,759
Identifiable intangible assets, less accumulated amortization ($M)($M)
8509189599981,0401,0751,0821,1271,1861,2261,2951,338
Accounts payable ($M)($M)
419452507445410508420433404420405411
Total current liabilities ($M)($M)
2,6822,0612,0532,1731,8073,3663,3853,4121,7021,7971,9091,889
Long-term debt, net of discount and issuance costs ($M)($M)
8,2999,0489,0459,0427,0695,2315,2275,2206,5746,5636,5626,564
Total liabilities ($M)($M)
11,78511,92911,92112,0759,7619,5029,4439,4679,1239,2059,2969,295
Retained earnings ($M)($M)
15,24614,65314,18313,79813,59312,87212,37511,96811,80611,12410,69610,295
Total Zoetis Inc. shareholders' equity ($M)($M)
3,3033,1483,2333,4155,3984,9774,6554,7705,2344,9665,0584,997
Cash Flow Statement — Net cash provided by operating activities ($M)($M)5
824655401848936605515905951502595897
Depreciation and amortization ($M)($M)
119119119122122124119123121127126126
Share-based compensation expense ($M)($M)
272625222222171918191817
Capital expenditures ($M)($M)
107117110159138146178216167132140198
Net cash used in investing activities ($M)($M)
-262-300-87-165-168-212-203126-178-132-131-210
Net cash used in financing activities ($M)($M)
-718-813-840-495-134-564-677-745-628-763-524-397

28 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar & 2026 Fiscal Year Alignment: Zoetis Inc. reports on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026). Through FY2025, subsidiaries operating outside the United States closed their fiscal year on November 30; beginning in Q1 2026, Zoetis eliminated the one-month reporting lag so all U.S. and international operations report on a uniform December 31 fiscal calendar.
  • Core operational & commercial KPIs (Groups 1–6) cover: (1) Segment & Segment × Species Revenue ($2,391M in Q3 2026 / $9,467M in FY25 across U.S. $1,246M [Companion Animal $980M, Livestock $266M], International $1,116M [Companion Animal $585M, Livestock $531M], and Contract Manufacturing & Human Health $29M) along with the full Reported, Foreign Exchange, Operational, Divestiture, and Organic Operational growth bridge and MD&A Price vs. Volume drivers; (2) Species Revenue Breakdown across Companion Animal ($1,565M in Q3 2026: Dogs & Cats $1,492M, Horses $73M) and Livestock ($797M in Q3 2026: Cattle $439M, Swine $120M, Poultry $108M, Fish $98M, Sheep & Other $32M), correcting the 2018–2025 Form 10-K XBRL preparer tag swap between DogsAndCatsMember and HorsesMember; (3) Veterinary Product Categories ($2,362M in Q3 2026: Parasiticides $564M, Vaccines $496M, Dermatology $419M, Anti-Infectives $286M, Pain & Sedation $247M, Other Pharmaceuticals $175M, Animal Health Diagnostics $125M, Other Non-Pharmaceuticals $50M, plus Medicated Feed Additives divested Oct 31, 2024), Blockbuster Franchises from earnings call transcripts (Key Dermatology $396M, Simparica Franchise $358M, OA Pain mAbs $137M in Q3 2026 across U.S. & International), and Top Product/Customer Concentration; (4) Geographic Revenue across the U.S. and 14 Key International Markets (Brazil $114M, Australia $104M, U.K. $75M, Canada $70M, China $61M, Germany $51M, Mexico $49M, France $37M, Spain $37M, Chile $34M, Italy $30M, Japan $26M, Other Developed $183M, Other Emerging $245M in Q3 2026); (5) Segment P&L & Margins (U.S. Gross Margin 82.2% and Segment Earnings $830M; International Gross Margin 68.9% and Segment Earnings $600M in Q3 2026) and Reconciling Items; and (6) Non-GAAP Adjusted P&L ($720M Adjusted Net Income / $1.75 Adjusted Diluted EPS in Q3 2026; $2,847M / $6.41 in FY25) and Full-Year 2026 Guidance evolution.
  • Balance Sheet, Capital, Workforce & ESG KPIs (Groups 7–10) cover: (7) Gross-to-Net Sales Deductions ($395M accrued rebate liability and $260M AR allowance at FY25), Inventories by Manufacturing Stage ($2,383M net at Q3 2026: Finished Goods $1,123M, WIP $798M, Raw Materials $462M), PP&E by Asset Class ($3,365M net at Q3 2026; 21 internal manufacturing sites in FY25), Goodwill ($2,859M) & Intangibles ($1,093M net at Q3 2026), and Operating Leases; (8) Debt & 5-Year Maturity Schedule ($5,921M noncurrent long-term debt at Q3 2026), Share Repurchases ($1,967M in Q1–Q3 2026) & SBC by Award Type, Restructuring Reserves, Defined Benefit Pensions & Income Taxes; (9) Global Workforce (14,500 employees: 6,800 U.S., 7,700 International; 1,700 R&D colleagues; 3,900 sales colleagues; 87% engagement in FY25), CEO Pay Ratio (244:1 / $80,592 median employee in FY25), Form 11-K Zoetis Savings Plan ($2.11B net assets at FY25), Safety (0.31 TIR / 0.18 LTIR in FY25), Form SD 3TG Smelters, and Scope 1/2/3 GHG Emissions, Energy, Water & Waste; and (10) FRED Pharmaceutical & Livestock Benchmarks and Core Financial Statements from Postgres DB.
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Không hiện vì thiếu các kỳ gần đây (21)

  • Revenue by Operating Segment, Segment × Species & Growth Bridge (Volume, Price, FX & Divestitures) › Total Consolidated Revenue ($M) › MD&A Operational Revenue Change YoY ($M) › MD&A Revenue Driver — Price Growth / (Decline) Contribution (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Brazil ($M) › Brazil — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Australia ($M) › Australia — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › United Kingdom ($M) › United Kingdom — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Canada ($M) › Canada — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Germany ($M) › Germany — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › China ($M) › China — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › France ($M) › France — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Mexico ($M) › Mexico — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Spain ($M) › Spain — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Italy ($M) › Italy — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Chile ($M) › Chile — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Japan ($M) › Japan — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Other Developed Markets ($M) › Other Developed Markets — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Other Emerging Markets ($M) › Other Emerging Markets — Divestitures impact YoY (%)
  • Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Total International Markets Revenue — Divestitures impact YoY (%)
  • Commercial Reach — Countries Where Products Are Sold ('over 100 countries' — bounded disclosure in 10-K/8-K; exact XBRL count of ~45 direct-operation countries is included in Group 4)
  • R&D Pipeline — Active Research and Development Programs ('over 300 programs' — bounded disclosure in Form 10-K Item 1)
  • External Contract Manufacturing Network — Third-Party CMOs ('more than 90 third-party contract manufacturing organizations' — bounded disclosure in Form 10-K Item 1)
  • Osteoarthritis Pain mAbs — Cumulative Doses & Treated Patients ('over 30 million doses of Librela and Solensia distributed globally' / 'over 1.2 million patients' — bounded cumulative callouts in earnings calls)
  • Companion Animal Addressable Market Projections — Dermatology & Triple-Combination TAM ('$2.5B by 2028' / '$4.5B by 2028' — forward-looking multi-year industry TAM estimates from Q4 call)

Dữ liệu cập nhật 2026-11-10.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Revenue by Operating Segment, Segment × Species & Growth Bridge (Volume, Price, FX & Divestitures)

Revenue by Animal Species — Companion Animal (Dogs & Cats, Horses) & Livestock (Cattle, Swine, Poultry, Fish, Sheep)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Zoetis

See a number that looks wrong?